Desmethoxyyangonin
Names | |
---|---|
IUPAC name
4-methoxy-6-[(E)-2-phenylethenyl]-2H-pyran-2-one
| |
Other names
5,6-Dehydrokawain
4-methoxy-6-[(E)-2-phenylvinyl]-2-pyranone | |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C14H12O3 | |
Molar mass | 228.247 g·mol−1 |
Appearance | white to faint yellow powder |
Density | 1.18 g/mL |
Melting point | 148 °C (298 °F; 421 K) |
Boiling point | 440 °C (824 °F; 713 K) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Desmethoxyyangonin or 5,6-dehydrokawain is one of the six major kavalactones found in the Piper methysticum (kava) plant.
Pharmacology
Desmethoxyyangonin is a reversible inhibitor of monoamine oxidase B (MAO-B).[1] Kava is able to increase dopamine levels in the nucleus accumbens[2] and desmethoxyyangonin likely contributes to this effect. This, along with the potential increases of serotonin and other catecholamine concentrations, may be responsible for the purported attention-promoting effects of kava.
Desmethoxyyangonin has marked activity on the induction of CYP3A23.[3]
References
- ^ Uebelhack, R (September 1998). "Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava)". Pharmacopsychiatry. 31 (5): 187–192. doi:10.1055/s-2007-979325. PMID 9832350.
{{cite journal}}
: Unknown parameter|coauthors=
ignored (|author=
suggested) (help)CS1 maint: date and year (link) - ^ Baum, SS (October 1998). "Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 22 (7): 1105–1120. doi:10.1016/S0278-5846(98)00062-1. PMID 9829291.
{{cite journal}}
: Unknown parameter|coauthors=
ignored (|author=
suggested) (help)CS1 maint: date and year (link) - ^ Ma, Yuzhong (November 2004). "Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of CYP3A23". Drug Metabolism and Disposition. 32 (11): 1317–1324. doi:10.1124/dmd.104.000786. PMID 15282211.
{{cite journal}}
: Unknown parameter|coauthors=
ignored (|author=
suggested) (help)
See also